Laura Barnabei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Laura Barnabei has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Jesus Arribas
Institute of Oncology Research 1 Bellinzona
3 shared publications - Chiara Tarantelli
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
3 shared publications - Emanuele Zucca
Institute of Oncology Research Bellinzona Switzerland
3 shared publications - Filippo Spriano
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
3 shared publications - Francesco Bertoni
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
3 shared publications - Luciano Cascione
Institute of Oncology Research, Faculty of Biomedical Sciences, USI, Bellinzona, Switzerland
3 shared publications
Latest Publications
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
New genetic predisposition to early-onset autoimmunity in human : implication of the NF-κB pathway
Nouvelle prédisposition génétique à l'auto-immunité précoce chez l'homme : implication de la voie NFkB: Le lupus érythémateux systémique (LES) est une maladie auto-immune et inflammatoire caractérisée par une production excessive d'auto-anticorps et de cytokines pro-inflammatoires, notamment l'interféron de type 1. Afin d'identifier de nouveaux facteurs génétiques associés au LES, un whole exome sequencing (WES) nous a permis d'identifier deux mutations différentes du gène RELA chez 3 patients LES ayant débuté à l'âge adulte ou pédiatrique. RELA code la protéine p65 qui est une sous-unité du facteur de transcription NF-κB. Les mutations retrouvées H86N et R329X de RELA conduisent à l'activation constitutive de la voie NF-κB dans lymphocytes des patients, illustrée par une localisation nucléaire spontanée. Ces trois patients présentent également une expression élevée des gènes stimulés par l'interféron (ISG). En parallèle, la co-expression, dans une lignée cellulaire immortalisée, de la forme sauvage et mutante de RELA et d'un gène rapporteur (Luciferin) sous le contrôle d'un promoteur IFN-I, a confirmé l'implication des mutants de RELA dans la production de l'interféron de type I. De plus, une mutation de novo du gène RELB a été identifié chez un patient présentant un syndrome poly-autoimmun de type IPEX. De même que pour les mutants RELA, le mutant RELB conduit à une relocalisation nucléaire de RELB/p62 à l'état basal entrainant une activité spontanée de la voie NF-κB. De plus, la forme mutée de RELB est associée à une augmentation de la production d'IFN de type I. L'ensemble de ces nouvelles données démontre le rôle essentiel de RELA et RELB dans la régulation de la voie de l'interféron de type 1 dans les maladies auto-immunes.
- 3 April 2026
- Published by Agence Bibliographique de l'Enseignement Supérieur
New genetic predisposition to early-onset autoimmunity in human : implication of the NF-κB pathway
Nouvelle prédisposition génétique à l'auto-immunité précoce chez l'homme : implication de la voie NFkB: Le lupus érythémateux systémique (LES) est une maladie auto-immune et inflammatoire caractérisée par une production excessive d'auto-anticorps et de cytokines pro-inflammatoires, notamment l'interféron de type 1. Afin d'identifier de nouveaux facteurs génétiques associés au LES, un whole exome sequencing (WES) nous a permis d'identifier deux mutations différentes du gène RELA chez 3 patients LES ayant débuté à l'âge adulte ou pédiatrique. RELA code la protéine p65 qui est une sous-unité du facteur de transcription NF-κB. Les mutations retrouvées H86N et R329X de RELA conduisent à l'activation constitutive de la voie NF-κB dans lymphocytes des patients, illustrée par une localisation nucléaire spontanée. Ces trois patients présentent également une expression élevée des gènes stimulés par l'interféron (ISG). En parallèle, la co-expression, dans une lignée cellulaire immortalisée, de la forme sauvage et mutante de RELA et d'un gène rapporteur (Luciferin) sous le contrôle d'un promoteur IFN-I, a confirmé l'implication des mutants de RELA dans la production de l'interféron de type I. De plus, une mutation de novo du gène RELB a été identifié chez un patient présentant un syndrome poly-autoimmun de type IPEX. De même que pour les mutants RELA, le mutant RELB conduit à une relocalisation nucléaire de RELB/p62 à l'état basal entrainant une activité spontanée de la voie NF-κB. De plus, la forme mutée de RELB est associée à une augmentation de la production d'IFN de type I. L'ensemble de ces nouvelles données démontre le rôle essentiel de RELA et RELB dans la régulation de la voie de l'interféron de type 1 dans les maladies auto-immunes.
- Open Access
Pharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models
Background: CXCR4 is a chemokine receptor frequently implicated in the pathogenesis and treatment resistance of B-cell lymphomas and other tumor types. Thus, CXCR4 targeting is explored using various approaches, including small molecules, antibodies, and short peptides. Here, we investigated the antitumor effects of the CXCR4 pharmacological inhibition with the synthetic peptides SPX5551 and balixafortide, as single agents and in combination, in various B-cell lymphoma models. Methods: Binding modalities were assessed via molecular docking and simulation. In vitro assays evaluated single-agent and combinatorial effects of CXCR4 antagonists with BTK, PI3K, and conventional therapies across 20 lymphoma cell lines, including models with acquired resistance. Transcriptomic analyses and mechanistic studies elucidated the pathways modulated by combined CXCR4 and BTK inhibition. Results: Structural modeling confirmed similar CXCR4 binding modes for SPX5551 and balixafortide. SPX5551 displayed minimal single-agent activity but restored sensitivity to BTK and PI3K inhibitors in resistant marginal zone lymphoma (MZL) models. Across mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL) models, SPX5551 enhanced the efficacy and/or potency of ibrutinib, copanlisib, rituximab, and R-CHOP. In MCL, co-treatment with SPX5551 and ibrutinib synergistically induced apoptosis, inhibited NF-κB and AKT signaling, and led to broader transcriptomic repression of tumor-promoting pathways compared to either agent alone. Conclusions: Although CXCR4 inhibitors alone show limited cytotoxicity, their combination with standard and targeted therapies significantly enhances anti-lymphoma effects, particularly in drug-resistant settings. These findings provide a strong rationale for clinical evaluation of CXCR4 blockade as a combinatorial strategy in B-cell lymphomas.
Open AccessPharmacological inhibition of CXCR4 increases the anti-tumor activity of conventional and targeted therapies in B-cell lymphoma models
Background: CXCR4 is a chemokine receptor frequently implicated in the pathogenesis and treatment resistance of B-cell lymphomas and other tumor types. Thus, CXCR4 targeting is explored using various approaches, including small molecules, antibodies, and short peptides. Here, we investigated the antitumor effects of the CXCR4 pharmacological inhibition with the synthetic peptides SPX5551 and balixafortide, as single agents and in combination, in various B-cell lymphoma models. Methods: Binding modalities were assessed via molecular docking and simulation. In vitro assays evaluated single-agent and combinatorial effects of CXCR4 antagonists with BTK, PI3K, and conventional therapies across 20 lymphoma cell lines, including models with acquired resistance. Transcriptomic analyses and mechanistic studies elucidated the pathways modulated by combined CXCR4 and BTK inhibition. Results: Structural modeling confirmed similar CXCR4 binding modes for SPX5551 and balixafortide. SPX5551 displayed minimal single-agent activity but restored sensitivity to BTK and PI3K inhibitors in resistant marginal zone lymphoma (MZL) models. Across mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL) models, SPX5551 enhanced the efficacy and/or potency of ibrutinib, copanlisib, rituximab, and R-CHOP. In MCL, co-treatment with SPX5551 and ibrutinib synergistically induced apoptosis, inhibited NF-κB and AKT signaling, and led to broader transcriptomic repression of tumor-promoting pathways compared to either agent alone. Conclusions: Although CXCR4 inhibitors alone show limited cytotoxicity, their combination with standard and targeted therapies significantly enhances anti-lymphoma effects, particularly in drug-resistant settings. These findings provide a strong rationale for clinical evaluation of CXCR4 blockade as a combinatorial strategy in B-cell lymphomas.
- Open Access
ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
BTK and PI3K inhibitors are among the drugs approved for the treatment of patients with lymphoid neoplasms. Although active, their ability to lead as single agents to long-lasting complete remission is rather limited especially in the lymphoma setting. This indicates that tumor cells often develop resistance to the drugs. Here, we show that the overexpression of ERBB4 and its ligands represents a modality for B cell neoplastic cells to bypass the anti-tumor activity of BTK and PI3K inhibitors and that targeted pharmacological interventions can restore sensitivity to the small molecules. We started from a marginal zone lymphoma (MZL) cell line, Karpas-1718, kept under prolonged exposure to the PI3Kδ inhibitor idelalisib until acquisition of resistance, or with no drug. Cells underwent transcriptome, miRNA and methylation profiling, whole exome sequencing, and pharmacological screening which led to the identification of the overexpression of ERBB4 and its ligands HBEGF and NRG2 in the resistant cells. Cellular and genetic experiments demonstrated the involvement of this axis in blocking the anti-tumor activity of various BTK and PI3K inhibitors, currently used in the clinical setting. Addition of recombinant HBEGF induced resistance to BTK and PI3K inhibitors in parental cells but also in additional lymphoma models. Combination with the ERBB inhibitor lapatinib was beneficial in resistant cells and in other lymphoma models already expressing the identified resistance factors. Multi-omics analysis underlined that an epigenetic reprogramming affected the expression of the resistance-related factors, and pretreatment with demethylating agents or EZH2 inhibitors overcame the resistance. Resistance factors were shown to be expressed in clinical samples, further extending the findings of the study. In conclusions, we identified a novel ERBB4-driven mechanism of resistance to BTK and PI3K inhibitors and treatments that appear to overcome it. Key points A mechanism of secondary resistance to the PI3Kδ and BTK inhibitors in B cell neoplasms driven by secreted factors. Resistance can be reverted by targeting ERBB signaling.
Open AccessERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms
BTK and PI3K inhibitors are among the drugs approved for the treatment of patients with lymphoid neoplasms. Although active, their ability to lead as single agents to long-lasting complete remission is rather limited especially in the lymphoma setting. This indicates that tumor cells often develop resistance to the drugs. Here, we show that the overexpression of ERBB4 and its ligands represents a modality for B cell neoplastic cells to bypass the anti-tumor activity of BTK and PI3K inhibitors and that targeted pharmacological interventions can restore sensitivity to the small molecules. We started from a marginal zone lymphoma (MZL) cell line, Karpas-1718, kept under prolonged exposure to the PI3Kδ inhibitor idelalisib until acquisition of resistance, or with no drug. Cells underwent transcriptome, miRNA and methylation profiling, whole exome sequencing, and pharmacological screening which led to the identification of the overexpression of ERBB4 and its ligands HBEGF and NRG2 in the resistant cells. Cellular and genetic experiments demonstrated the involvement of this axis in blocking the anti-tumor activity of various BTK and PI3K inhibitors, currently used in the clinical setting. Addition of recombinant HBEGF induced resistance to BTK and PI3K inhibitors in parental cells but also in additional lymphoma models. Combination with the ERBB inhibitor lapatinib was beneficial in resistant cells and in other lymphoma models already expressing the identified resistance factors. Multi-omics analysis underlined that an epigenetic reprogramming affected the expression of the resistance-related factors, and pretreatment with demethylating agents or EZH2 inhibitors overcame the resistance. Resistance factors were shown to be expressed in clinical samples, further extending the findings of the study. In conclusions, we identified a novel ERBB4-driven mechanism of resistance to BTK and PI3K inhibitors and treatments that appear to overcome it. Key points A mechanism of secondary resistance to the PI3Kδ and BTK inhibitors in B cell neoplasms driven by secreted factors. Resistance can be reverted by targeting ERBB signaling.
- Open Access
A first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity in hematological cancers
Hematological cancers are among the most common cancers in adults and in children. Despite significant improvements in therapies, many patients still succumb to the disease, therefore, novel therapies are needed. The Wiskott-Aldrich syndrome protein (WASp) family proteins regulate actin assembly in conjunction with the Arp2/3 complex, a ubiquitous nucleation factor. WASp is expressed exclusively in hematopoietic cells and exists in two allosteric conformations, auto-inhibited and active conformations. Here, we describe the development of EG-011, a first-in-class small molecule activator of the WASp auto-inhibited form. EG-011 possesses in vitro and in vivo anti-tumor activity as single agent in lymphoma, leukemia and multiple myeloma, including models of secondary resistance to PI3K, BTK and proteasome inhibitors. The in vitro activity was confirmed in a lymphoma xenograft. Actin polymerization induced by EG-011 was demonstrated with multiple techniques. Transcriptome analysis highlighted homology with drugs inducing actin polymerization. Key points EG-011 is a novel small molecule with anti-tumor activity in hematological cancers, including resistant lymphoma and multiple myeloma models EG-011 is a first-in-class small molecule activator of the auto-inhibited form of the Wiskott-Aldrich syndrome protein (WASp)
Open AccessA first-in-class Wiskott-Aldrich syndrome protein (WASp) activator with anti-tumor activity in hematological cancers
Hematological cancers are among the most common cancers in adults and in children. Despite significant improvements in therapies, many patients still succumb to the disease, therefore, novel therapies are needed. The Wiskott-Aldrich syndrome protein (WASp) family proteins regulate actin assembly in conjunction with the Arp2/3 complex, a ubiquitous nucleation factor. WASp is expressed exclusively in hematopoietic cells and exists in two allosteric conformations, auto-inhibited and active conformations. Here, we describe the development of EG-011, a first-in-class small molecule activator of the WASp auto-inhibited form. EG-011 possesses in vitro and in vivo anti-tumor activity as single agent in lymphoma, leukemia and multiple myeloma, including models of secondary resistance to PI3K, BTK and proteasome inhibitors. The in vitro activity was confirmed in a lymphoma xenograft. Actin polymerization induced by EG-011 was demonstrated with multiple techniques. Transcriptome analysis highlighted homology with drugs inducing actin polymerization. Key points EG-011 is a novel small molecule with anti-tumor activity in hematological cancers, including resistant lymphoma and multiple myeloma models EG-011 is a first-in-class small molecule activator of the auto-inhibited form of the Wiskott-Aldrich syndrome protein (WASp)
- Open Access
- 1 December 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (6) , 1176-1185
Type I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*
SummaryBackground. The outbreak of chilblain‐like lesions (CLL) during the COVID‐19 pandemic has been reported extensively, potentially related to SARS‐CoV‐2 in
- 1 December 2021
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 185 (6) , 1176-1185
Open AccessType I interferon response and vascular alteration in chilblain‐like lesions during the COVID‐19 outbreak*
SummaryBackground. The outbreak of chilblain‐like lesions (CLL) during the COVID‐19 pandemic has been reported extensively, potentially related to SARS‐CoV‐2 in
- 31 August 2017
- Published by Morressier GmbH
THE ROLE OF ACTIVATING TMEM173/STING MUTATIONS IN THE CONTROL OF THE ADAPTIVE IMMUNE RESPONSE
- 31 August 2017
- Published by Morressier GmbH
THE ROLE OF ACTIVATING TMEM173/STING MUTATIONS IN THE CONTROL OF THE ADAPTIVE IMMUNE RESPONSE